Omeros Corporation Stock News

Cubist Systematic Strategies LLC boosted its holdings in Omeros Co. (NASDAQ:OMER) by 57.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 53,774 shares of the biopharmaceutical companys stock after purchasing an additional 19,687 shares during the period. Cubist Systematic Strategies LLC owned []

Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Complement 3 Glomerulopathy (C3G) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering.

Omeros Corporation (OMER) CEO Greg Demopulos on Q3 2021 Results - Earnings Call Transcript

Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.  Treatment with nar

The average of price targets set by Wall Street analysts indicates a potential upside of 192% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2021, on Tuesday, Novembe

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic stem cell transplant-associated thrombotic mi

Bad news the company received today from the FDA surprised investors more than it probably should have.

The stock price of Omeros Corporation (NASDAQ: OMER) fell by over 16% pre-market today. This is why it happened.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Bi

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised

NEW YORK--(BUSINESS WIRE)-- #Omeros--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Omeros Corporatio